The BioNTech investor guarantees, out of concern for the scarcity, that vaccines shall be delivered for the second shot

© Reuters.

FRANKFURT (Reuters) – European countries should use all available vaccine doses from biotech company BioNTech and its partner Pfizer (NYSE 🙂 because due to a planned production ramp-up there will be enough for the required second booster shot, said BioNTech's largest investor.

Some countries have been believed to withhold some vaccines for fear of lack of the required second dose to be given three weeks after the first vaccination.

Pfizer said last week it would have to cut delivery of the recordings to Europe by early February in order to improve production capacity for later production increases.

In an interview with the monthly Manager Magazin, the managing director of the investment vehicle of the biotech investors Thomas and Andreas Struengmann, who hold around half of the shares in BioNTech, said that Denmark had accepted the delivery cuts and had not withheld any quantities of the second boost dose of the two- Shot regime.

"Denmark, for example, is a role model," Helmut Jeggle, head of the Struengmann brothers' holding company, Athos, told the magazine when asked why Europe was falling behind in its vaccination campaign.

In parts of Germany, half of the divided vaccine doses had been stored in order to reserve a refresher shot for each recipient of the first shot within the prescribed three-week interval.

"This level of inventory is not required as we will do everything we can in the first quarter to actually deliver the promised quantities, despite some hiccups at the Belgian site in Puurs for a week or two," Jeggle was quoted as saying.

($ 1 = 0.8243 euros)

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may suffer from using this data.

Fusion Media or anyone involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please be fully informed about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.

Related Articles